MyopiaProMOCNCT06647472
Proteomic Analysis on Myopic Children Using Orthokeratology Lenses With Good or Poor Myopic Control
An observational study of Myopia and Healthy, run by Vejle Hospital at 1 site in Denmark.
Trial summary
The key objective of the study is to gain an understanding of the biochemical processes that contribute to orthokeratology lenses being more effective in specific individuals compared to others. Read more about this study
- Who is it for?
- Ages 5 to 14 years
- Conditions the study is for
- Myopia, Healthy, Orthokeratology
- How many people
- 20 participants
- Where
- 1 siteDenmark
- Study dates
- 15 Nov 2024to Dec 2026
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 5 to 14 years
- All sexes
- Child
Study population: Children who are currently being treated with orthokeratology lenses at the Ophthalmic Department, Vejle Hospital, University Hospital of Southern Denmark.
Who may be able to join
- Children treated with orthokeratology lenses.
- Children on or above the 95th percentile of myopia growth curves for European children at the time of treatment initiation.
- Treatment and follow-up duration ≥ 6 months.
Who cannot join
- Current use of eye drops.
- Objective signs of dry eyes on slit-lamp examination.
- Active eye infection.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Proteomic Analysis on Myopic Children Using Orthokeratology Lenses With Good or Poor Myopic Control. The ProMOC Study
The key objective of the study is to gain an understanding of the biochemical processes that contribute to orthokeratology lenses being more effective in specific individuals compared to others. With this knowledge, we hope to optimize treatment effectiveness in those currently experiencing less favorable outcomes from treatment in the future.
The primary aim is to investigate differences in protein levels in children using orthokeratology lenses with various effects of myopia control.
Hypothesis: There is a significant difference in the expression of molecules in children with various effects of myopia control.
- Conditions
- Myopia, Healthy, Orthokeratology
- Medical subject headings
- Myopia
What is being measured
The primary outcome is the main question the study is designed to answer.
Difference in protein levels measured by mass spectrometry label-free quantification (LFQ) between children using orthokeratology lenses with different levels of myopia control effectiveness
Measured: At baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Oct 2024
- Study start15 Nov 2024
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MyopiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 20 participants (actual)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Vejle Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- University of Aarhus
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06647472
- Sponsor's protocol ID
- The ProMOC study
- Acronym
- ProMOC
- Status last verified
- Jul 2026
- First submitted
- 15 Oct 2024
- Last updated
- 21 Jul 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Proteomic Analysis on Myopic Children Using Orthokeratology Lenses With Good or Poor Myopic Control. The ProMOC Study
- ClinicalTrials.gov ID
- NCT06647472
- Acronym / sponsor ID
- ProMOC / The ProMOC study
- Conditions
- Myopia, Healthy, Orthokeratology
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Vejle HospitalUniversity, hospital or other
- Collaborators
- University of Aarhus
- Study start
- 15 Nov 2024 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 17 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The key objective of the study is to gain an understanding of the biochemical processes that contribute to orthokeratology lenses being more effective in specific individuals compared to others. With this knowledge, we hope to optimize treatment effectiveness in those currently experiencing less favorable outcomes from treatment in the future.
The primary aim is to investigate differences in protein levels in children using orthokeratology lenses with various effects of myopia control.
Hypothesis: There is a significant difference in the expression of molecules in children with various effects of myopia control.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Target follow-up
- 1 Day
Who may qualify
- Ages
- 5 to 14 years
- Sex
- All
- Age groups
- Child
- Study population
- Children who are currently being treated with orthokeratology lenses at the Ophthalmic Department, Vejle Hospital, University Hospital of Southern Denmark.
Key inclusion criteria (3 listed)
- Children treated with orthokeratology lenses.
- Children on or above the 95th percentile of myopia growth curves for European children at the time of treatment initiation.
- Treatment and follow-up duration ≥ 6 months.
Key exclusion criteria (3 listed)
- Current use of eye drops.
- Objective signs of dry eyes on slit-lamp examination.
- Active eye infection.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Difference in protein levels measured by mass spectrometry label-free quantification (LFQ) between children using orthokeratology lenses with different levels of myopia control effectiveness
Time frame: At baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Myopia
Recruiting
Managing Premyopia in Chinese Children Using Artificial Intelligence Assisted Defocus Incorporated Multiple Segments Based Spectacle Lens: a Randomized Controlled Clinical Trial
Pre-myopia, Myopia
Not yet recruiting
BRIGHT-LIGHT: Studying Red Light Therapy for Severe Short-Sightedness or Short-Sightedness That Worsens Despite Standard Treatment
Myopia, Myopia Progressing
Not yet recruiting
Clinical Performance and Outcomes After Toric Lens Transition
Astigmatism
Active, not recruiting
Effect of IOP Lowering on Progressive HM
High Myopia, Intraocular Pressure
Recruiting
Evaluation of a New Laser Refractive Vision Correction Using the TENEO™ 317 Model 2
Hyperopia and Myopia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Myopia and Healthy, run by Vejle Hospital at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 21 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Difference in protein levels measured by mass spectrometry label-free quantification (LFQ) between children using orthokeratology lenses with different levels of myopia control effectiveness (time frame: At baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jul 2026.